Brainomix Secures $18M in Series C Funding to Revolutionize Stroke Imaging Worldwide

Brainomix, a pioneer in harnessing the power of artificial intelligence to transform medical scans, is excited to announce that it has raised £18,000,000 in its latest funding round. Since its inception as a spin-out from the University of Oxford in 2010, Brainomix has been dedicated to turning ordinary scans into extraordinary insights because every patient deserves expert-level care, anywhere. The new funds will accelerate the global deployment of Brainomix 360, our flagship platform designed to enhance stroke imaging interpretation for neurologists, interventionalists, and radiologists. By delivering the right insights to the right people at the right time, Brainomix 360 not only improves patient care but also integrates seamlessly into existing radiology workflows, making it both impactful and scalable. The infusion of capital comes at a pivotal moment as we further expand our award-winning, AI-powered imaging biomarkers and software solutions into new markets, particularly in stroke and lung care. Our commitment to empowering physicians worldwide with rapid, accurate diagnostic insights will be reinforced with this investment, enabling us to further refine our technology and extend our reach to critical care centers around the globe. With the backing of our investors, Brainomix is poised to drive the next phase of innovation, ensuring that every patient benefits from cutting-edge, life-saving advancements in medical imaging. We invite healthcare providers, partners, and stakeholders to reach out today to discover how Brainomix is reshaping the future of stroke pathways and patient care.